Purple Biotech Secures $50M ATM Offering
Ticker: PPBT · Form: 6-K · Filed: Sep 19, 2025 · CIK: 1614744
Sentiment: neutral
Topics: atm-offering, financing, equity-raise
TL;DR
Purple Biotech just inked a $50M ATM deal with H.C. Wainwright to sell shares.
AI Summary
On September 19, 2025, Purple Biotech Ltd. entered into an At The Market Offering Agreement (ATM Agreement) with H.C. Wainwright & Co., LLC. This agreement allows the company to sell up to $50 million of its ordinary shares.
Why It Matters
This ATM agreement provides Purple Biotech with a flexible way to raise capital, potentially funding future research and development or operational needs.
Risk Assessment
Risk Level: medium — ATM agreements can dilute existing shareholders and their success depends on market conditions and the company's ability to execute sales.
Key Numbers
- $50.0M — ATM Offering Capacity (Maximum amount of ordinary shares Purple Biotech can sell under the agreement.)
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- H.C. Wainwright & Co., LLC (company) — Underwriter for ATM Agreement
- September 19, 2025 (date) — Date of ATM Agreement
- $50 million (dollar_amount) — Maximum offering amount
FAQ
What is the purpose of the ATM Agreement?
The filing states the ATM Agreement allows Purple Biotech Ltd. to sell its ordinary shares from time to time through H.C. Wainwright & Co., LLC.
What is the maximum amount Purple Biotech can raise through this agreement?
Purple Biotech Ltd. can sell up to $50 million of its ordinary shares under the ATM Agreement.
Who is the agent for the ATM offering?
H.C. Wainwright & Co., LLC is the agent for the At The Market Offering Agreement.
When was the ATM Agreement entered into?
The ATM Agreement was entered into on September 19, 2025.
What type of securities can be sold under the ATM Agreement?
The agreement allows for the sale of Purple Biotech Ltd.'s ordinary shares.
Filing Stats: 784 words · 3 min read · ~3 pages · Grade level 14.1 · Accepted 2025-09-19 17:28:14
Key Financial Figures
- $2,300,000 — ng an aggregate offering price of up to $2,300,000. Termination of the Jefferies ATM Agre
- $7,729,691 — 17 ADSs for aggregate gross proceeds of $7,729,691, at an average price of $7.86 per ADS p
- $7.86 — s of $7,729,691, at an average price of $7.86 per ADS pursuant to the Jefferies ATM P
Filing Documents
- ea0258001-6k_purple.htm (6-K) — 15KB
- ea025800101ex1-1_purple.htm (EX-1.1) — 213KB
- ea025800101ex5-1_purple.htm (EX-5.1) — 13KB
- ea025800101ex5-2_purple.htm (EX-5.2) — 10KB
- ex5-1_001.jpg (GRAPHIC) — 20KB
- ex5-2_001.jpg (GRAPHIC) — 6KB
- 0001213900-25-089661.txt ( ) — 289KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. PURPLE BIOTECH LTD. (the “Registrant”) Date: September 19, 2025 By: /s/ Gil Efron Name: Gil Efron Title: Chief Executive Officer 2